SMAD2 and cancer: In TMV-treated Treg, increased expression levels of phospho-STAT3 and phospho-SMAD2/3 and of IL-10 and TGF-β1 expression as well as production may be responsible for attenuating anti-tumor immune responses in cancer patients.